FDA slaps hold on Finch's microbiome C. difficile treatment, as biotech blames Covid-19 and old manufacturer
Drugmakers working on treatments for C. difficile infections are having a bad week.
Just one day after Pfizer reported its C. difficile vaccine candidate did not hit the primary endpoint in a Phase III study, Finch Therapeutics is finding itself in a similar position. The biotech said Tuesday its microbiome treatment for the infection was placed on clinical hold by the FDA last week, with regulators seeking more info on Finch’s screening protocols.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.